ReviewFrontiers in immunology2026
Non-anticoagulant heparins: glycan-mediated immune modulation and therapeutic applications.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging Role, Molecular Mechanisms, and Therapeutic Potential of 2-O, 3-O Desulfated Heparin (ODSH) Across Inflammatory and Vascular Diseases.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-anticoagulant heparins (NAHs) are modified derivatives of heparin that retain many of the biological activities of the parent compound while exhibiting reduced or absent anticoagulant effects. These modifications have unlocked new therapeutic potentials in various diseases, including inflammatory disorders, cancer, sepsis, and viral infections. This review explores the chemical modifications of NAHs, their mechanisms of action, structure-activity relationships, and therapeutic applications. NAHs exert anti-inflammatory, anticancer, antiviral, and vascular protective effects by interacting with key proteins like heparanase, P-selectin, and HMGB1. Furthermore, their application in drug delivery systems, such as hydrogels and nanoparticles, enhances localized therapeutic efficacy. The promising results from preclinical and clinical studies position NAHs as a valuable class of drugs with diverse therapeutic applications, particularly in oncology, infectious diseases, and critical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.